EuMederis Pharmaceuticals, Inc. is a drug discovery and development company making use of our patented EuPort™ technology to provide Best-in-Class peptide pharmaceuticals with improved bioavailability, prolonged duration of action and optimized pharmaceutical properties.
Initial pharmaceutical candidates that demonstrate and validate the EuPort™ technology are directed at indications in pain, in control of osteoporosis and hypoparathyroidism, and in the reversal of the inflammatory component of the metabolic syndrome. EuMederis has completed proof of concept studies entailing compound synthesis and in vivo testing through our highly-regarded network of partners in the contract research organization world.
These pharmaceutical candidates make use of a broadly-based, proprietary technology (EuPort™) developed by our Founder, based on his many years of successful research on peptide drug candidates.
Our current pipeline contains preclinical candidates for each of the three clinical indications cited above.
